keyword
MENU ▼
Read by QxMD icon Read
search

hepatitis viral

keyword
https://www.readbyqxmd.com/read/27926593/cost-effectiveness-of-direct-acting-anti-viral-treatment-in-hepatitis-c-infected-liver-transplant-candidates-with-compensated-cirrhosis-and-hepatocellular-carcinoma
#1
James Salazar, Varun Saxena, James G Kahn, John P Roberts, Neil Mehta, Michael Volk, Jennifer C Lai
BACKGROUND: HCV(+) donors represent an effective strategy to increase liver donor availability to HCV-infected recipients. However, many HCV(+) transplant candidates are now receiving treatment with direct acting anti-virals (DAA) that lower the risk of posttransplant HCV recurrence but could make the patient ineligible for HCV(+) livers. METHODS: We compared pretransplant DAA treatment versus deferred DAA treatment using a cost-effectiveness decision analysis model to estimate incremental cost-effectiveness ratios (ICERs; cost per quality-adjusted life year [QALY] gained) from the societal perspective across a range of HCV(+) liver availability rates...
December 6, 2016: Transplantation
https://www.readbyqxmd.com/read/27925362/ns5a-inhibitors-for-the-treatment-of-hepatitis-c-infection
#2
Stefano Gitto, Nesrine Gamal, Pietro Andreone
Today, we are witnessing a new era for the treatment of hepatitis C with excellent rates of virologic response and very good safety profiles. Among the many classes of direct acting antivirals, the inhibitors of non-structural protein 5A are particularly interesting. NS5A is phosphorylated protein with a relevant role in viral replication. HCV-NS5A inhibitors show high potency, very good safety profile and high barrier to resistance. The amazing in vitro effectiveness of this class is associated with great efficacy in clinical trials in combination protocols with antivirals of other classes, with sustained virological response (SVR) obtained in more than 90% of patients...
December 7, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27925300/the-importance-of-serum-biglycan-levels-as-a-fibrosis-marker-in-patients-with-chronic-hepatitis-b
#3
Rafiye Ciftciler, Seren Ozenirler, Aysegul Atak Yucel, Mustafa Cengiz, Gulbanu Erkan, Erkan Buyukdemirci, Cemile Sönmez, Guldal Yılmaz Esendaglı
BACKGROUND: Liver biopsy is recommended in the majority of patients with chronic viral hepatitis for fibrosis evaluation. Because of the potential risks of liver biopsy, many studies related to non-invasive biomarkers of hepatic fibrosis have been performed. We aimed to assess the diagnostic value of serum biglycan as a non-invasive fibrosis marker in chronic hepatitis B patients. METHODS: This study included 120 patients with biopsy-proven hepatitis B patients and 60 healthy controls...
December 7, 2016: Journal of Clinical Laboratory Analysis
https://www.readbyqxmd.com/read/27924246/adenovirus-and-culture-negative-sepsis-in-a-preterm-neonate
#4
Mohannad Moallem, Eunkyung Song, Preeti Jaggi, Miriam R Conces, Adriana E Kajon, Pablo J Sánchez
Background Respiratory viral infections remain an underrecognized cause of morbidity and mortality among preterm infants in the neonatal intensive care unit (NICU). Case Report An eight day old, 650 gram birth weight, 23 weeks' gestational age female developed "culture-negative" sepsis manifested by respiratory deterioration, hypoxia, leukocytosis, and thrombocytopenia. She was diagnosed with pneumonia and hepatitis due to adenovirus HAdV-D (H29F9) by polymerase chain reaction (PCR) testing, but died at the age of 18 days despite treatment with cidofovir and immune globulin intravenous...
October 2016: American Journal of Perinatology Reports
https://www.readbyqxmd.com/read/27924186/treatment-of-chronic-hepatitis-c-infection-with-sofosbuvir-based-regimens-in-a-commercially-insured-patient-population
#5
John Barron, Yiqiong Xie, Sze-Jung Wu, Jeff White, Joseph Singer, Bernard Tulsi, Alan Rosenberg
BACKGROUND: The response to treatment with direct-acting antiviral agents in patients with chronic hepatitis C virus (HCV) is not well-characterized in the real-world setting. OBJECTIVE: To describe patients' response to 3 sofosbuvir-based treatment regimens among commercially insured patients with chronic HCV. METHODS: In this observational study, we identified patients with HCV who started sofosbuvir treatment with 1 of 3 sofosbuvir-based regimens between December 1, 2013, and April 30, 2014, in the HealthCore Integrated Research Database, a large managed care repository...
September 2016: American Health & Drug Benefits
https://www.readbyqxmd.com/read/27924098/erratum-association-of-hepatitis-b-core-related-antigen-with-hepatitis-b-virus-reactivation-in-occult-viral-carriers-undergoing-high-risk-immunosuppressive-therapy
#6
Wai-Kay Seto, DannyKa-Ho Wong, ThomasSau-Yan Chan, Yu-Yan Hwang, James Fung, Kevin Sze-Hang Liu, Harinder Gill, Yuk-Fai Lam, Ka-Shing Cheung, Albert K W Lie, Ching-Lung Lai, Yok-Lam Kwong, Man-Fung Yuen
No abstract text is available yet for this article.
December 2016: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/27923923/antiviral-innate-immune-response-interferes-with-the-formation-of-replication-associated-membrane-structures-induced-by-a-positive-strand-rna-virus
#7
Diede Oudshoorn, Barbara van der Hoeven, Ronald W A L Limpens, Corrine Beugeling, Eric J Snijder, Montserrat Bárcena, Marjolein Kikkert
: Infection with nidoviruses like corona- and arteriviruses induces a reticulovesicular network of interconnected endoplasmic reticulum (ER)-derived double-membrane vesicles (DMVs) and other membrane structures. This network is thought to accommodate the viral replication machinery and protect it from innate immune detection. We hypothesized that the innate immune response has tools to counteract the formation of these virus-induced replication organelles in order to inhibit virus replication...
December 6, 2016: MBio
https://www.readbyqxmd.com/read/27923693/post-treatment-resistance-analysis-of-hepatitis-c-virus-from-phase-2-and-3-clinical-trials-of-ledipasvir-sofosbuvir
#8
David Wyles, Hadas Dvory-Sobol, Evguenia S Brian Svarovskaia Doehle, Ross Martin, Nezam H Afdhal, Kris V Kowdley, Eric Lawitz, Diana M Brainard, Michael D Miller, Hongmei Mo, Edward J Gane
BACKGROUND & AIMS: Ledipasvir/sofosbuvir combination treatment in phase 3 clinical trials, resulted in sustained viral suppression in 94%-99% of patients. Characterization of drug resistance in treatment failures may help inform retreatment options. METHODS: We performed NS5A and NS5B deep sequencing of HCV from patients infected with genotype (GT) 1 who participated in ledipasvir/sofosbuvir phase 2 and 3 clinical trials. RESULTS: Fifty-one of 2144 (2...
December 3, 2016: Journal of Hepatology
https://www.readbyqxmd.com/read/27923614/antiviral-therapy-inhibits-viral-reactivation-and-improves-survival-after-repeat-hepatectomy-for-hepatitis-b-virus-related-recurrent-hepatocellular-carcinoma
#9
Shengyu Huang, Yong Xia, Zhengqing Lei, Qifei Zou, Jun Li, Tian Yang, Kui Wang, Zhenlin Yan, Xuying Wan, Feng Shen
BACKGROUND: To explore the impact of antiviral therapy (AVT) on short- and long-term outcomes after re-hepatectomy for patients with recurrent HBV-related hepatocellular carcinoma (HCC). STUDY DESIGN: The data of 583 consecutive patients who underwent re-hepatectomy for intrahepatic recurrence of HBV-related HCC after initial hepatectomy between 2006 and 2011 at the Eastern Hepatobiliary Surgery Hospital were analyzed. Tumor re-recurrence, recurrence to death survival (RTDS) and overall survival (OS) were compared using the Kaplan-Meier method and log-rank test...
December 3, 2016: Journal of the American College of Surgeons
https://www.readbyqxmd.com/read/27922198/dnmt1-modulation-in-chronic-hepatitis-b-patients-and-hypothetic-influence-on-mitochondrial-dna-methylation-status-during-long-term-nucleo-t-side-analogues-therapy
#10
Giordano Madeddu, Silvia Ortu, Giovanni Garrucciu, Ivana Maida, Michela Melis, Alberto Augusto Muredda, Maria Stella Mura, Sergio Babudieri
Inhibition of viral replication is the most important goal in patients with Hepatitis B virus chronic infection (CHB). Currently, five oral nucleo(t)side analogues (NAs), including Lamivudine, Adefovir, Telbivudine, Entecavir and Tenofovir, have been approved for treatment. The widespread use of NAs has also been linked with a progressive growth of unlikely anomaly attributable to mitochondrial dysfunctions, not previously recognized. Here we explore the hypothesis that NAs may cause persistent epigenetic changes during prolonged NAs therapy in CHB patients...
December 6, 2016: Journal of Medical Virology
https://www.readbyqxmd.com/read/27922197/variability-in-the-performance-characteristics-of-igg-anti-hev-assays-and-its-impact-on-reliability-of-seroprevalence-rates-of-hepatitis-e
#11
Maja Kodani, Nourine Ahmed, Alexandra Tejada-Strop, Amanda Poe, Maxine M Denniston, Jan Drobeniuc, Saleem Kamili
Hepatitis E is a major public health problem in developing countries and is increasingly being recognized as a cause of substantial sporadic viral hepatitis infections in industrialized countries. Variable rates of hepatitis E seroprevalence have been reported from the same geographic regions depending on the assay used. In this study, we evaluated the performance characteristics of four assays which included two commercial assays, Wantai HEV-IgG ELISA kit (Wantai, China) and DS-EIA-ANTI-HEV-G kit (DSI, Italy), one NIH-developed immunoassay (NIH-55K, Kuniholm et al...
December 6, 2016: Journal of Medical Virology
https://www.readbyqxmd.com/read/27920641/severe-de-novo-hepatitis-b-recovered-from-late-onset-liver-insufficiency-with-prolonged-ascites-and-hypoalbuminemia-due-to-hepatitis-b-virus-genotype-bj-with-precore-mutation
#12
Akira Sato, Toshiya Ishii, Fumiaki Sano, Takayuki Yamada, Hideaki Takahashi, Nobuyuki Matsumoto
De novo hepatitis B is associated with a high risk of hepatic failure often resulting in fatal fulminant hepatitis even when nucleotide analogues are administered. A 77-year-old female developed de novo hepatitis B after R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) treatment for diffuse large B-cell lymphoma. Hepatitis B virus (HBV) isolated from the patient was of genotype Bj, with a precore mutation (G1896A) exhibiting an extremely high viral load at the onset of hepatitis...
September 2016: Case Reports in Gastroenterology
https://www.readbyqxmd.com/read/27920482/hepatitis-c-virus-therapy-with-peg-interferon-and-ribavirin-in-myanmar-a-resource-constrained-country
#13
Naomi Khaing Than Hlaing, Debolina Banerjee, Robert Mitrani, Soe Htet Arker, Kyaw San Win, Nyan Lin Tun, Zaw Thant, Khin Maung Win, K Rajender Reddy
AIM: To investigate peg-interferon (peg-IFN) and ribavirin (RBV) therapy in Myanmar and to predict sustained virologic response (SVR). METHODS: This single-center, open-label, study was conducted in Myanmar between 2009 and 2014. A total of 288 patients infected with HCV genotypes 1, 2, 3 and 6 were treated with peg-IFN alpha-2a (180 μg/wk) or alpha-2b (50 to 100 μg as a weight-based dose) and RBV as a weight-based dose (15 mg/kg/d). Treatment duration was 48 wk for genotypes 1 and 6, 24 wk for genotype 2, and 24 or 48 wk for genotype 3 based on rapid virologic response (RVR)...
November 21, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/27920481/new-real-time-pcr-method-to-identify-single-point-mutations-in-hepatitis-c-virus
#14
Qian Chen, Irene Belmonte, Maria Buti, Leonardo Nieto, Damir Garcia-Cehic, Josep Gregori, Celia Perales, Laura Ordeig, Meritxell Llorens, Maria Eugenia Soria, Rafael Esteban, Juan Ignacio Esteban, Francisco Rodriguez-Frias, Josep Quer
AIM: To develop a fast, low-cost diagnostic strategy to identify single point mutations in highly variable genomes such as hepatitis C virus (HCV). METHODS: In patients with HCV infection, resistance-associated amino acid substitutions within the viral quasispecies prior to therapy can confer decreased susceptibility to direct-acting antiviral agents and lead to treatment failure and virological relapse. One such naturally occurring mutation is the Q80K substitution in the HCV-NS3 protease gene, which confers resistance to PI inhibitors, particularly simeprevir...
November 21, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/27920474/hepatitis-b-virus-upregulates-host-expression-of-%C3%AE-1-2-mannosidases-via-the-ppar%C3%AE-pathway
#15
Song Hu, Li-Bin Jiang, Xiao-Jing Zou, Wei Yi, De-Ying Tian
AIM: To assess the effects of hepatitis B virus (HBV) on the expression of host α-1,2-mannosidases and determine the underlying mechanisms. METHODS: We measured the expression levels of MAN1A1, MAN1A2, MAN1B1, and MAN1C1 in cell lines HepG2.2.15, HepN10, HepAD38 and HepG2 by Western blot. Viral antigens (HBsAg and HBeAg) in the culture medium were measured using the chemiluminescence method. HBV DNA quantification assays were performed using a commercial real-time PCR kit...
November 21, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/27920392/knowledge-attitudes-and-practices-of-health-care-workers-about-viral-hepatitis-b-and-c-in-south-kivu
#16
Tony Akilimali Shindano, Esto Bahizire, René Fiasse, Yves Horsmans
Health-care workers (HCWs) are at risk of infections associated with accidental exposure to blood, including viral hepatitis B (HBV) and C (HCV). A survey using a questionnaire was conducted on 250 HCW in Bukavu, an eastern town of the Democratic Republic of Congo, to analyze their attitude and knowledge about these two viruses. A response rate of 86.8% (217/250) was obtained. The mean age of respondents was 39.6 ± 9.8 years, in majority from paramedical staff (66.4%) and with more than 5 years of professional experience (60...
December 5, 2016: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/27917600/determination-of-hepatitis-b-phenotype-using-biochemical-and%C3%A2-serological-markers
#17
A M Di Bisceglie, M Lombardero, J Teckman, L Roberts, H L A Janssen, S H Belle, J H Hoofnagle
The aim of this study was to assess the validity of categorization of chronic hepatitis B viral infection into stages or phases based upon measures of disease activity and viral load, assuming these phenotypes will be useful for prognostication and determining the need for antiviral therapy. We assessed the phenotype of hepatitis B of 1,390 adult participants enrolled in the Hepatitis B Research Network Cohort Study, using a computer algorithm. Only 4% were immune tolerant, while 35% had chronic hepatitis B (18% e antigen positive and 17% e antigen negative) while 23% were inactive carriers...
December 5, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27917568/clinical-characteristics-and-outcomes-of-patients-with-recurrent-chronic-hepatitis-b-after-nucleos-t-ide-analog-withdrawal-with-stringent-cessation-criteria-a-prospective-cohort-study
#18
Zhirong Liu, Feng Liu, Lei Wang, Youde Liu, Meng Zhang, Tao Li
AIM: The aim of this study was to explore the clinical characteristics and outcomes of patients with recurrent chronic hepatitis B meeting the cessation criteria outlined by the 2008 Asian Pacific Association for the Study of the Liver guidelines. METHODS: In total, 223 chronic hepatitis B patients who met the cessation criteria and discontinued nucleos(t)ide analog therapy were prospectively included. They were monitored monthly during the first 4 months and every 3-6 months thereafter...
November 7, 2016: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/27917563/outcome-of-hepatitis-b-and-c-virus-associated-hepatocellular-carcinoma-occurring-after-renal-transplantation
#19
N Kanaan, C Raggi, E Goffin, M De Meyer, M Mourad, M Jadoul, C Beguin, B Kabamba, I Borbath, Y Pirson, Z Hassoun
Kidney transplant recipients (KTR) are subjected to immunosuppressive therapy that can enhance hepatitis B and C virus replication, leading to cirrhosis and hepatocellular carcinoma (HCC). The aim of this study was to assess the prevalence and outcome of HCC in KTR. Case-control study. Patients with chronic HBV and/or HCV infection who underwent kidney transplantation between 1976 and 2011 and subsequently developed HCC were compared to a control group of patients with chronic HBV and/or HCV infection, matched for gender and age at HCC diagnosis, who did not receive kidney transplantation...
December 5, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27917363/future-therapy-for-hepatitis-b-virus-role-of-immunomodulators
#20
REVIEW
Edward A Pham, Ryan B Perumpail, Benjamin J Fram, Jeffrey S Glenn, Aijaz Ahmed, Robert G Gish
Although currently available therapies for chronic hepatitis B virus infection can suppress viremia and provide long-term benefits for patients, they do not lead to a functional cure for most patients. Advances in our understanding of the virus-host interaction and the recent remarkable success of immunotherapy in cancer offer new and promising strategies for developing immune modulators that may become important components of a total therapeutic approach to hepatitis B, some of which are now in clinical development...
2016: Current Hepatology Reports
keyword
keyword
72437
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"